Japan targets “faster than FDA” medtech approvals, but reimbursement issues remain
This article was originally published in Clinica
Japanese medical device regulatory conditions are improving fast, at least, that is the intention behind recent groundbreaking medtech-specific legislation and a new five-year plan to speed device approvals. But device reimbursement levels remain in need of attention, says Philip Agress, AdvaMed senior vice-president of global strategy and analysis
You may also be interested in...
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.
The RSNA is the next global medtech exhibition and conference event to be run under a virtual format this fall.
COVID-19 put a dampener on Conmed’s 50th anniversary of operations, but CFO Todd Garner says the company is poised to resume its growth strategy, post-pandemic.